Denali Therapeutics (NASDAQ:DNLI) Upgraded to “Sell” at Wall Street Zen

Wall Street Zen upgraded shares of Denali Therapeutics (NASDAQ:DNLI) from a strong sell rating to a sell rating in a report issued on Saturday.

A number of other equities research analysts also recently issued reports on the stock. Leerink Partners decreased their price target on shares of Denali Therapeutics from $40.00 to $35.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 22nd. BTIG Research lifted their price objective on shares of Denali Therapeutics from $36.00 to $38.00 and gave the stock a “buy” rating in a research note on Wednesday, March 25th. Morgan Stanley boosted their target price on shares of Denali Therapeutics from $40.00 to $42.00 and gave the stock an “overweight” rating in a report on Thursday, March 26th. HC Wainwright increased their price target on shares of Denali Therapeutics from $32.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, March 26th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $40.00 price target on shares of Denali Therapeutics in a research report on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Denali Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $34.42.

Denali Therapeutics Stock Performance

NASDAQ DNLI opened at $19.62 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.16 and a quick ratio of 9.16. Denali Therapeutics has a 1-year low of $12.58 and a 1-year high of $23.77. The business has a 50 day simple moving average of $20.19 and a two-hundred day simple moving average of $18.86. The stock has a market capitalization of $3.11 billion, a PE ratio of -6.81 and a beta of 0.99.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.04. During the same period in the previous year, the firm earned ($0.78) EPS. On average, research analysts predict that Denali Therapeutics will post -2.86 EPS for the current fiscal year.

Institutional Investors Weigh In On Denali Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Foresite Capital Management VI LLC purchased a new stake in Denali Therapeutics in the 3rd quarter worth about $14,520,000. AlphaQuest LLC boosted its position in shares of Denali Therapeutics by 224.1% during the third quarter. AlphaQuest LLC now owns 74,422 shares of the company’s stock valued at $1,081,000 after buying an additional 51,458 shares during the period. Aberdeen Group plc grew its stake in shares of Denali Therapeutics by 23.4% during the third quarter. Aberdeen Group plc now owns 1,113,586 shares of the company’s stock valued at $16,169,000 after buying an additional 210,835 shares during the last quarter. Principal Financial Group Inc. grew its stake in shares of Denali Therapeutics by 18.5% during the third quarter. Principal Financial Group Inc. now owns 1,271,190 shares of the company’s stock valued at $18,458,000 after buying an additional 198,207 shares during the last quarter. Finally, Capricorn Fund Managers Ltd purchased a new stake in shares of Denali Therapeutics in the fourth quarter worth approximately $1,027,000. Hedge funds and other institutional investors own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.